Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview - Dose Escalation Ongoing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Foll

Protara Therapeutics Announces Third Quarter

2022 Financial Results and Business Overview

- Dose Escalation Ongoing in Phase 1 ADVANCED-1

Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer -

- Following Recent Feedback from the U.S. Food

and Drug Administration, Phase 2 Study of TARA-002 in Lymphatic Malformations Expected to Initiate in 2023 -

- Strong Cash, Cash Equivalents and Investments

Position of $107.1M as of September 30, 2022 Now Expected to Fund Operations Into 2H2024 -

NEW YORK, November 3, 2022 - Protara

Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare

diseases, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.

"We continue to make meaningful progress

with dose escalation in the ongoing Phase 1a portion of our ADVANCED-1 study of TARA-002 in non-muscle invasive bladder cancer (NMIBC),

and look forward to ultimately utilizing these data, as well as data from our ongoing preclinical work, to design effective later-stage

clinical trials in this indication," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "We are pleased

to share that we have received initial feedback from the U.S. Food and Drug Administration (FDA) on our proposed Phase 2 study protocol

evaluating TARA-002 in Lymphatic Malformations (LMs), and now expect to initiate the study in 2023. LMs represents a highly underserved

rare pediatric indication for which we believe TARA-002 could serve as a much-needed treatment option."

IV Choline Chloride in Intestinal Failure Associated

Liver Disease (IFALD)

Third Quarter 2022 Financial Results

TARA-002 is an investigational cell therapy in

development for the treatment of NMIBC and LMs for which it has been granted Rare Pediatric Disease Designation by the U.S. Food and Drug

Administration. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432,

a broad immunopotentiator marketed as Picibanil in Japan and Taiwan by Chugai Pharmaceutical Co., Ltd. Protara has successfully

demonstrated manufacturing comparability between TARA-002 and OK-432.

When TARA-002 is administered, it is hypothesized

that innate and adaptive immune cells within the cyst or tumor are activated and produce a strong immune cascade. Neutrophils, monocytes

and lymphocytes infiltrate the abnormal cells and various cytokines, including interleukins IL-2, IL-6, IL-8, IL-10, IL-12, interferon

(IFN)-gamma, tumor necrosis factor (TNF)-alpha, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor

are secreted by immune cells to induce a strong local inflammatory reaction and destroy the abnormal cells.

About Non-Muscle Invasive Bladder Cancer (NMIBC)

Bladder cancer is the 6th most common cancer in

the United States, with NMIBC representing approximately 80% of bladder cancer diagnoses. Approximately 65,000 patients are diagnosed

with NMIBC in the United States each year. NMIBC is cancer found in the tissue that lines the inner surface of the bladder that has not

spread into the bladder muscle.

About Lymphatic Malformations (LMs)

LMs are rare, congenital malformations of lymphatic

vessels resulting in the failure of these structures to connect or drain into the venous system. Most LMs are present in the head and

neck region and are diagnosed in early childhood during the period of active lymphatic growth, with more than 50% detected at birth and

90% diagnosed before the age of 3 years. The most common morbidities and serious manifestations of the disease include compression of

the upper aerodigestive tract, including airway obstruction requiring intubation and possible tracheostomy dependence; intralesional bleeding;

impingement on critical structures, including nerves, vessels, lymphatics; recurrent infection, and cosmetic and other functional disabilities.

About IV Choline Chloride and Intestinal Failure-associated

Liver Disease (IFALD)

IV Choline Chloride is an investigational, intravenous

(IV) phospholipid substrate replacement therapy initially in development for patients receiving parenteral nutrition (PN) who have IFALD.

Choline is a known important substrate for phospholipids that are critical for healthy liver function. Because PN patients cannot sufficiently

absorb adequate levels of choline and no available PN formulations contain sufficient amounts of choline to correct this deficiency, PN

patients often experience a prolonged progression to hepatic failure and death, with the only known intervention being a dual small bowel/liver

transplant. If approved, IV Choline Chloride would be the first approved therapy for IFALD. It has been granted Orphan Drug Designations

(ODDs) by the FDA for the treatment of IFALD and the prevention of choline deficiency in PN patients.

About Protara Therapeutics, Inc.

Protara is committed to identifying and advancing

transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lead program, TARA-002, an investigational

cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline

Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.

For more information, visit www.protaratx.com.

Forward-Looking Statements

Statements contained in this press release regarding

matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation

Reform Act of 1995. Protara may, in some cases, use terms such as "predicts," "believes," "potential,"

"proposed," "continue," "designed," "estimates," "anticipates," "expects,"

"plans," "intends," "may," "could," "might," "will," "should"

or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes

to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding Protara's

intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Protara's business strategy,

including its development plans for its product candidates and plans regarding the timing or outcome of existing or future clinical trials;

statements related to expectations regarding interactions with the FDA, including potential alignment with the FDA on, and finalization

of, clinical trial design for TARA-002 in pediatric LM patients; Protara's financial footing; statements regarding the anticipated

safety or efficacy of Protara's product candidates; and Protara's outlook for the remainder of the year. Because such statements

are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.

Factors that contribute to the uncertain nature of the forward-looking statements include: risks that Protara's financial guidance

may not be as expected, as well as risks and uncertainties associated with: Protara's development programs, including the initiation

and completion of non-clinical studies and clinical trials and the timing of required filings with the FDA and other regulatory agencies;

the impact of the COVID-19 pandemic on Protara's business and the global economy as well as the impact on Protara's contract

research organizations, study sites or other clinical partners; general market conditions; changes in the competitive landscape; changes

in Protara's strategic and commercial plans; Protara's ability to obtain sufficient financing to fund its strategic plans

and commercialization efforts; having to use cash in ways or on timing other than expected; the impact of market volatility on cash reserves;

the loss of key members of management; the impact of general U.S. and foreign, economic, industry, market, regulatory or political conditions;

and the risks and uncertainties associated with Protara's business and financial condition in general, including the risks and uncertainties

described more fully under the caption "Risk Factors" and elsewhere in Protara's filings and reports with the United

States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on

which they were made and are based on management's assumptions and estimates as of such date. Protara undertakes no obligation to

update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise,

except as required by law.

PROTARA THERAPEUTICS, INC.

Unaudited Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

PROTARA THERAPEUTICS, INC.

Unaudited Condensed Consolidated Statements

of Operations and Comprehensive Loss

(in thousands, except share and per share data)

Protara Therapeutics